[18F]fluoroestradiol radiation dosimetry in human PET studies
- PMID: 11337559
[18F]fluoroestradiol radiation dosimetry in human PET studies
Abstract
[18F]16alpha-fluoroestradiol (FES) is a PET imaging agent useful for the study of estrogen receptors in breast cancer. We estimated the radiation dosimetry for this tracer using data obtained in patient studies.
Methods: Time-dependent tissue concentrations of radioactivity were determined from blood samples and PET images in 49 patients (52 studies) after intravenous injection of FES. Radiation absorbed doses were calculated using the procedures of the MIRD committee, taking into account the variation in dose based on the distribution of activities observed in the individual patients. Effective dose equivalent was calculated using International Commission on Radiological Protection Publication 60 weights for the standard woman.
Results: The effective dose equivalent was 0.022 mSv/MBq (80 mrem/mCi). The organ that received the highest dose was the liver (0.13 mGy/MBq [470 mrad/mCi]), followed by the gallbladder (0.10 mGy/MBq [380 mrad/mCi]) and the urinary bladder (0.05 mGy/MBq [190 mrad/mCi]).
Conclusion: The organ doses are comparable to those associated with other commonly performed nuclear medicine tests. FES is a useful estrogen receptor-imaging agent, and the potential radiation risks associated with this study are well within accepted limits.
Similar articles
-
18F-Fluorothymidine radiation dosimetry in human PET imaging studies.J Nucl Med. 2003 Sep;44(9):1482-8. J Nucl Med. 2003. PMID: 12960196 Clinical Trial.
-
Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies.J Nucl Med. 1997 Oct;38(10):1631-6. J Nucl Med. 1997. PMID: 9379204
-
Assessment of human biodistribution and dosimetry of 4-fluoro-11beta-methoxy-16alpha-18F-fluoroestradiol using serial whole-body PET/CT.J Nucl Med. 2009 Jan;50(1):100-7. doi: 10.2967/jnumed.108.057000. Epub 2008 Dec 17. J Nucl Med. 2009. PMID: 19091905 Clinical Trial.
-
Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo: The Groningen Experience.Clin Nucl Med. 2016 Nov;41(11):844-851. doi: 10.1097/RLU.0000000000001347. Clin Nucl Med. 2016. PMID: 27607175 Review.
-
18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.J Nucl Med. 2016 Aug;57(8):1269-75. doi: 10.2967/jnumed.116.175596. Epub 2016 Jun 15. J Nucl Med. 2016. PMID: 27307345 Review.
Cited by
-
Human Absorbed Dose Estimation of 111In-DOTA-PR81 as a Novel High Potential Agent for Breast Cancer Imaging.J Med Phys. 2022 Apr-Jun;47(2):194-200. doi: 10.4103/jmp.jmp_72_21. Epub 2022 Aug 5. J Med Phys. 2022. PMID: 36212201 Free PMC article.
-
ZR-75-1 breast cancer models to study the utility of 18F-FES by PET imaging.Transl Cancer Res. 2021 Mar;10(3):1430-1438. doi: 10.21037/tcr-20-3228. Transl Cancer Res. 2021. PMID: 35116468 Free PMC article.
-
Targeting the estrogen receptor with metal-carbonyl derivatives of estradiol.Bioorg Med Chem Lett. 2012 Feb 15;22(4):1670-3. doi: 10.1016/j.bmcl.2011.12.111. Epub 2012 Jan 8. Bioorg Med Chem Lett. 2012. PMID: 22277281 Free PMC article.
-
Radiation dose estimates for [18F]5-fluorouracil derived from PET-based and tissue-based methods in rats.Mol Imaging Biol. 2008 Nov-Dec;10(6):341-8. doi: 10.1007/s11307-008-0160-5. Epub 2008 Aug 5. Mol Imaging Biol. 2008. PMID: 18679756
-
Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted 18F-Fluorthanatrace PET in Breast Cancer.J Nucl Med. 2024 Dec 3;65(12):1862-1868. doi: 10.2967/jnumed.124.268254. J Nucl Med. 2024. PMID: 39477499 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous